Feds probe ISTA promotions

ISTA Pharmaceuticals issued a statement reporting a subpoena received from the US Attorney's Office in Buffalo, “requesting the production of documents regarding promotional, educational and other activities relating to Xibrom (bromfenac sodium ophthalmic solution) 0.09%.”  

Xibrom is an ophthalmic solution indicated for the treatment of inflammation and ocular pain following cateract surgery.  Representatives of ISTA Pharmaceuticals were not immediately available for comment.

ISTA Pharmaceuticals previously reported clinical trial data showing “no statistically significant difference” between Xibrom and a new product, Xibrom QD.  Xibrom QD, to be taken once-per-day, would potentially replace Xibrom, taken twice-per-day.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.